Developing next-generation coronavirus drugs

Coronavirus protease inhibitors

We leverage our understanding of viral proteases, from decades of work engineering the proteases of hepatitis C virus and human rhinovirus and using their small-molecule inhibitors, to create highly potent inhibitors of coronavirus proteases. Our lead drugs feature high affinity, high oral bioavailability, high specificity, low reversibility, and robustness against mutations that allow escape from approved protease inhibitors.